SCHEMBL4151014

SCHEMBL4151014

Nc1ccnc2ccc(-c3ccc4cc[nH]c4c3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.46
EGFR P00533 4/20 0.44
BACE1 P56817 1/20 0.43
PI4K2A Q9BTU6 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
BRD4 O60885 1/20 0.42
APP P05067 1/20 0.41
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA7 P36544 1/20 0.40
CHRNA10 Q9GZZ6 1/20 0.40
CHRNA9 Q9UGM1 1/20 0.40
PIK3CD O00329 4/20 0.40
PIK3CA P42336 4/20 0.40
MTOR P42345 4/20 0.40
ABL1 P00519 3/20 0.40
HCK P08631 3/20 0.40
SRC P12931 3/20 0.40
KDR P35968 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147845 0.89 MAP3K11 (0.48) NR4A2EGFRPI4K2ABRD4PIK3CD
SCHEMBL729497 0.80 PIK3CA (0.60) PIK3CDPIK3CAMTORPIK3CBPIK3CG
SCHEMBL4146232 0.77 PIK3CD (0.51) NR4A2PIK3CDABL1PIK3CBPIK3CG
SCHEMBL4151090 0.73 MAP4K4 (0.60) NR4A2EGFRBACE1PIK3CDPIK3CA
SCHEMBL29061683 0.73 MAP4K4 (0.60) NR4A2EGFRBACE1PIK3CDPIK3CA
SCHEMBL14321745 0.73 BACE1 (0.58) BACE1ADORA2AADORA1BRD4APP
SCHEMBL14827715 0.71 QPCT (0.53) BRD4APPCHRNB4CHRNA3CHRNA7
SCHEMBL29725526 0.71 ACVR1 (0.56) NR4A2PIK3CANCF1
SCHEMBL30989203 0.71 ADORA2A (0.53) EGFRBACE1PI4K2AADORA2AADORA1
SCHEMBL5758549 0.70 NR4A2 (0.56) NR4A2EGFRPIK3CDPIK3CAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds DICKSON JR JOHN K 2009-03-12 US disclosed
US-7452887-B2 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AMPHORA DISCOVERY CORPORATION (US) 2008-11-18 US disclosed
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AGRIUS GROUP, LLC. 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds ATP5ME, ABCG2, ATP5MG NR4A2 1882/4885EGFR 4447/4885BACE1 905/4885
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK NR4A2 3517/4885EGFR 4792/4885BACE1 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.